Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

French 'reverse off-label' prescribing vote angers pharma industry

This article was originally published in SRA

Executive Summary

The pharmaceutical industry has hit out once more against the growing trend by governments in the EU to promote as a means of saving money the off-label use of drugs in indications for which an approved medicine is already available. The reaction came in response to a vote by the French National Assembly (the lower house) on 8 July to approve an amendment to the government's draft social security budget bill that would allow the off-label use of medicines as long as no identical product existed (previously it was only allowed if no authorized product existed)1.

You may also be interested in...



US FDA's Pediatric Experts, Not Review Division, Should Have Final Say On Pediatric Trials, Former Official Says

Former Associate Commissioner Janice Soreth says views of pediatric experts should take precedence over those of division directors regarding pediatric trials.

US FDA's Office Of New Drug Leaders Listen To Stakeholders

Twenty-five officials of FDA's Office of New Drugs gather to hear recommendations from stakeholders on what they can do to improve drug development programs.

Biosimilar Sponsors Want Off-The-Record Labeling Discussions With US FDA

Hoping to avoid litigation discovery, sponsors ask FDA for avenue to explain patent issues during labeling discussions written record; negotiations for BsUFA III may be opportunity to create such a process.

UsernamePublicRestriction

Register

PS117862

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel